Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

• ClinicalTrials.gov Identifier: NCT00097695
• Recruitment Status: Completed
• First Posted: November 29, 2004
• Results First Posted: December 24, 2013
• Last Update Posted: June 9, 2021
• Sponsor: Shire
• Information provided by (Responsible Party): Takeda ( Shire )

Study Description

Brief Summary:

The purpose of this study is to assess the efficacy and safety of Icatibant, a bradykinin antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with hereditary angioedema (HAE).

Condition or disease	Intervention/treatment	Phase
Angioedema	Drug: Icatibant; Drug: Placebo	Phase 3

Detailed Description:

This Phase II/III study consisted of two parts: A controlled phase and An Open label extension(OLE) phase. The controlled phase describes the double blind part of the study and was intended to evaluate the efficacy of icatibant in decreasing the time to onset of symptom relief compared with placebo for the first treated cutaneous and/or abdominal attack in randomised patients. Patients experienced a laryngeal attack were not randomised, but treated with open label icatibant according to the controlled phase procedures and assessments. The outcome of this group was to be reported descriptively. After treatment of the first attack in the controlled phase, the patients were eligible to enter the OLE phase. In the OLE phase, patients who experienced angioedema attacks severe enough to warrant treatment were to be treated with s.c. icatibant as appropriate until the end of the study.The OLE phase became a modified open label extension where all 56 patients who had been randomised and the last randomised patient had concluded the double-blind phase. The modified open label extension period permitted treatment for patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the double blind phase was still ongoing.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 84 participants
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema
• Actual Study Start Date: December 28, 2004
• Actual Primary Completion Date: July 17, 2006
• Actual Study Completion Date: July 17, 2006

Arms and Interventions

Arm	Intervention/treatment
Experimental: Icatibant- Randomized; Patients who were randomized to icatibant in the controlled phase after they had an eligible first in-study attack.	Drug: Icatibant; 30 mg (3mL) subcutaneous icatibant injection in the abdominal region; Other Name: Brand name, Firazyr®
Placebo Comparator: Placebo-Randomized; Patients who were randomized to placebo in the controlled phase after they had an eligible first in-study attack.	Drug: Placebo; Solution for injection, matched to study drug Single dose: 3 mL
Experimental: Controlled Open-label / laryngeal attack; Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.	Drug: Icatibant; 30 mg (3mL) subcutaneous icatibant injection in the abdominal region; Other Name: Brand name, Firazyr®
Experimental: Untreated Patients at the baseline; Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing (they were not treated during the Controlled phase but treated with icatibant during the Open Label Extension Phase (OLE) )	Drug: Icatibant; 30 mg (3mL) subcutaneous icatibant injection in the abdominal region; Other Name: Brand name, Firazyr®

Outcome Measures

Primary Outcome Measures :

1. Time to Onset of Symptom Relief (TOSR) [ Time Frame: 5 days ]
   The primary efficacy endpoint was TOSR assessed by the patient using a Visual Analogue Scale (VAS). The VAS is a scale used to measure intensity of each symptom of the attack at baseline and at the pre-determined time points throughout treatment period. It consists of a horizontal 10cm line, with the 0 point corresponding to a state where patient experiences no symptoms at all and the 10cm point represents the worst symptoms ever experienced by patient. The patient indicates his/her current state of symptoms by drawing a mark across the horizontal line. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the 3 primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe.

Secondary Outcome Measures :

1. Time to Regression (Start of Improvement) According to Patient [ Time Frame: 5 days ]
   This parameter assessed the time to regression (start of improvement) of observable(visible) symptoms according to the patients. Patients were asked "Report date and time when you feel that your symptoms start to improve".
2. Time to Almost Complete Symptom Relief [ Time Frame: 5 days ]
   The time to almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least 3 consecutive measurements for all symptom.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age above 18 years;
• Documented diagnosis of HAE Type I or II (confirmed complement 1 esterase inhibitor [C1-INH] deficiency);
• Current edema be in the cutaneous, abdominal and/or laryngeal areas;
• Current edema be moderate to severe according to the investigator's Symptom Score.

Exclusion Criteria:

• Diagnosis of angioedema other than HAE, for example, acquired angioedema (AAE);
• Participation in a clinical trial of another investigational medicinal product (IMP) within the past month;
• Treatment with any pain medication since onset of the current edema attack;
• Treatment with replacement therapy, including C1-INH products (e.g. human C1-INH preparations), less than 3 days from onset of the current edema attack;
• Treatment with ACE inhibitors (e.g. Lotensin, Prinivil, Accupril);
• Evidence of severe, symptomatic coronary artery disease based on medical history or screening examination;
• Serious concomitant illnesses that the physician considers to be a contraindication for participation in the trial;
• Pregnancy and/or breast-feeding.

Contacts and Locations

Locations

United States, District of Columbia

Georgetown University Hospital, Lombardi Cancer Center

Washington, District of Columbia, United States, 20007-2197

Sponsors and Collaborators

Shire

Investigators

• Study Director: Study Director; Takeda

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Malbrán A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A, Hébert J, Gleich GJ, Hurewitz D, Jacobson KW, Bernstein JA, Khan DA, Kirkpatrick CH, Resnick D, Li H, Fernández Romero DS, Lumry W. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol. 2014 Aug;177(2):544-53. doi: 10.1111/cei.12358.

Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):532-41. doi: 10.1056/NEJMoa0906393. Erratum in: N Engl J Med. 2010 Oct 7;363(15):1486.

• Responsible Party: Shire
• ClinicalTrials.gov Identifier: NCT00097695
• Other Study ID Numbers: JE049 #2103; FAST1 ( Other Identifier: Shire HGT )
• First Posted: November 29, 2004
• Results First Posted: December 24, 2013
• Last Update Posted: June 9, 2021
• Last Verified: May 2021

Keywords provided by Takeda ( Shire ):

Hereditary Angioedema; C1 inhibitor deficiency; HAE; Icatibant; Bradykinin antagonist; acute attack; subcutaneous

Additional relevant MeSH terms:

Angioedema; Angioedemas, Hereditary; Vascular Diseases; Cardiovascular Diseases; Urticaria; Skin Diseases, Vascular; Skin Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Hereditary Complement Deficiency Diseases; Primary Immunodeficiency Diseases; Genetic Diseases, Inborn; Immunologic Deficiency Syndromes; Icatibant; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Inflammatory Agents; Antirheumatic Agents; Bradykinin B2 Receptor Antagonists; Bradykinin Receptor Antagonists; Molecular Mechanisms of Pharmacological Action; Complement Inactivating Agents; Immunosuppressive Agents; Immunologic Factors